Kyverna Therapeutics Aktie News

In November, Seeking Alpha welcomed 24 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The Academic Investor, recommending Galaxy Digital; Richard Doxtator, presenting on Moonlake Immunotherapeutics; and ML Research, writing about Sezzle—all rated Strong Buys. Analysts' diverse interests range from technology (AI, in particular) to ...

Kyverna Therapeutics receives a strong buy rating with a $55 price target, driven by revolutionary Phase 2 data for KYV-101 in myasthenia gravis. KYV-101 demonstrated double the efficacy of standard care and enabled 100% of patients to achieve drug-free remission, with a best-in-class safety profile. The platform is significantly de-risked, with experienced management, strong financials, and cl...

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026

EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, Nove...

Initial funding of $25 million from the first of four tranches  Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS), while also accelerating pre-launch activities Topline data readout of registrational Phase 2 SPS trial now expected in early 2026; narrowed from p...

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)

EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, October 29, 2025 at 8:00 AM ET to discuss the interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 in ...